Angsuman Chakraborty03 Oct 2008 07:23 am
John McNeish, an executive director of global Research & development (R&D) at the company, reveals that Pfizer, a renown drug maker is going to establish a second regenerative medicine unit in Cambridge in November.
This announcement was done at a recent stem cell expo. They say that this time the focus will be on researching in ophthalmology and diseases of the central nervous system area.
McNeish, himself will be running this US unit, with Cambridge UK that would eventually have 50 to 60 scientists working on stem cell therapies. They will be collaborating with academic researchers and smaller biotech companies, which is fabulous news for businesses in the East of England bio cluster.
McNeish told reporters at a recent conference that Pfizer had already agreed a number of small collaborations and had several works in hand that he hope to be announced in the next months or so. He also believes that other global pharmaceutical corporations will adopt the regenerative medicine which will be pioneered by Pfizer.
Pfizer, the world’s largest drug maker has its first regenerative medicinal unit in Cambridge, Massachusetts. The main aim to the unit is to concentrate on stem cell therapies in relation to heart disease and diabetes.
Source: https://www.businessweekly.co.uk/
Filed under Adult Stem Cell, Stem Cell | 1 Comment
Related?
Pfizer is injecting $100Millions into stem cell research May 9th, 2009 Pharmaceutical giant Pfizer announced a $100Millions support into its own stem cell development program. Pfizer's cash injection is the single highest funding the stem cell discipline has ever received from the corporate sector, the paper reports.
New "Stem Cell Sciences" license sanctioned for Cambridge University October 16th, 2008 Latest news reveals that Cambridge University for its growing reputation as a centre of excellence for stem cell research is going to receive a new license from Stem Cell Sciences plc (SCS). The researchers expects that this new achievement will boost their work and will help them to overcome all constraints during their research in stem cell field.
Stanford to get world's largest stem cell research building soonOctober 27th, 2008 Stem cell research is likely to have a major boost within next few days.The Lorry I. Lokey Stem Cell Research Building is likely will begin construction Oct.
Cord Blood Bank: World's Largest in IndiaOctober 8th, 2005 The world's largest umbilical cord blood bank is to be set up in Mumbai, India through a $20 million investment from the South Korean biotech company, Histostem. It aims to provide stem cells for transplant surgeons globally.
US researchers find technique to reprogram adult mammalian cells into induced pluripotent stemcellsOctober 26th, 2008 University of Cambridge researchers have described the technique that is enable to reprogram adult mammalian cells into authentic induced pluripotent stem (iPS) cells. The finding has been published in the PLoS Biology, the peer-reviewed scientific journal from the Public Library of Science (PLoS)(1).
Pfizer announces stem cell research center November 18th, 2008 Pfizer, an international pharmaceutical company has announced to open a new stem cell research center in the UK. The Pfizer Regenerative Medicine unit will be act as a biotechnology hub to develop future treatments aimed at preventing disabilities, repairing damaged organs and combating degenerative diseases.
World's First Baby Tooth Stem Cell BankJune 27th, 2006 BioEden (registered with the FDA), is the first fully operational processing laboratory and storage bank for primary teeth stem cells to open in the U.S. Their state-of-the-art facilities are located in Austin, Texas, and will serve children and their families nationwide.
FDA offers Aldagen to improve ALD-101 a novel stem cell therapyOctober 31st, 2008 In the latest announcement done by Aldagen, Inc., the company revealed about a new drug designation that Food and Drug Administration has offered to improve the outcome of metabolic diseases undergoing Umbilical Cord blood transplantation. The announcement was made on 30th of October, 2008 by the company officials.
One Response
Leave a Comment
John McNeish, an executive director of global Research & development (R&D) at the company, reveals that Pfizer, a renown drug maker is going to establish a second regenerative medicine unit in Cambridge in November.
May 9th, 2009 at 4:52 pm
[...] had its own independent research unit, Pfizer Regenerative Medicine, based in both Cambridge, England and Cambridge, Massachusetts. The unit conduct research that is aimed at developing new [...]